source
- Replimune's oncolytic virus therapy Tudriqev receives FDA accelerated approval for advanced melanomaThe U.S. Food and Drug Administration has granted approval to Replimune's melanoma treatment, ending a series of earlier rejections after an advisory panel advocated for the drug. The therapy, pre…
- Medicare delay adds seven years before AbbVie drug price talks, advocacy group saysA consumer advocacy group says a policy change by the Trump administration delayed Medicare’s selection of an AbbVie drug for price negotiations by seven years. The delay occurred as the Centers f…